Mereo BioPharma Group plc
Mereo BioPharma Group plc
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||
Assets Current | ||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 30 | 36 | 41 | 49 | 56 | 62 | 70 | 81 | 87 | 49 | 57 | |||||
Prepaid Expense And Other Assets Current | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 4 | 4 | 3 | 5 | |||||
Assets Current | 33 | 40 | 45 | 52 | 61 | 67 | 75 | 87 | 94 | 53 | 64 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Finite Lived Intangible Assets Net | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Assets | 35 | 41 | 46 | 54 | 63 | 68 | 76 | 89 | 96 | 56 | 66 | |||||
Liabilities | ||||||||||||||||
Liabilities Current | ||||||||||||||||
Accounts Payable Current | 1 | 3 | 1 | 1 | 1 | 3 | 2 | 2 | 3 | 2 | 2 | |||||
Accrued Liabilities Current | 2 | 2 | 2 | 4 | 5 | 3 | 4 | 4 | 4 | 3 | 5 | |||||
Convertible Notes Payable Current | - | - | 0 | 0 | 0 | 0 | 6 | 6 | 5 | 5 | 0 | |||||
Derivative Liabilities Current | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Operating Lease Liability Current | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Other Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | |||||
Liabilities Current | 6 | 6 | 4 | 6 | 8 | 7 | 14 | 14 | 15 | 11 | 9 | |||||
Convertible Long Term Notes Payable | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 4 | |||||
Derivative Liabilities Noncurrent | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | |||||
Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |||||
Other Liabilities Noncurrent | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | |||||
Liabilities | 6 | 7 | 5 | 7 | 8 | 8 | 15 | 16 | 17 | 13 | 16 | |||||
Stockholders Equity | ||||||||||||||||
Common Stock Value | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Additional Paid In Capital | 552 | 551 | 550 | 548 | 546 | 544 | 540 | 536 | 535 | 487 | 486 | |||||
Treasury Stock Common Value | - | - | - | - | - | - | 0 | 0 | 0 | 0 | -1 | |||||
Retained Earnings Accumulated Deficit | -515 | -508 | -501 | -494 | -487 | -472 | -463 | -456 | -441 | -429 | -420 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -12 | -13 | -11 | -11 | -9 | -15 | -19 | -11 | -18 | -18 | -17 | |||||
Stockholders Equity | 29 | 34 | 41 | 47 | 54 | 60 | 61 | -73 | 79 | 43 | 51 | |||||
Liabilities And Stockholders Equity | 35 | 41 | 46 | 54 | 63 | 68 | 76 | 89 | 96 | 56 | 66 | |||||
Common Stock Par Or Stated Value Per Share | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | |||||
Common Stock Shares Issued | 160 | 160 | 159 | 159 | 159 | 159 | 155 | 155 | 154 | 140 | 140 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 27.24% | 36.18% | 39.43% | - | - | - | - | - | - | - | - | - |
| 2025 | 18.10% | 23.71% | -28.45% | 6.63% | 22.89% | 14.46% | 16.38% | -71.19% | -75.14% | -8.86% | -30.75% | -13.30% |
| 2024 | 7.89% | 14.51% | 22.08% | 14.89% | 17.02% | 13.83% | -8.05% | -9.02% | -26.59% | -2.95% | -5.49% | 16.46% |
| 2023 | - | - | - | - | - | - | - | - | - | -12.00% | 6.67% | 41.67% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Mereo BioPharma Group plc (MREO) — SEC Financial Statements & Analysis
Mereo BioPharma Group plc (MREO) is a pharmaceutical preparations company, incorporated in X0. Mereo BioPharma Group plc trades on Nasdaq as: MREO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Mereo BioPharma Group plc reported a -124.60% year-over-year revenue growth, a Gross Profit Margin of 29.27% (TTM), a Debt-to-Equity ratio of 0.21x, a Price-to-Sales (P/S) ratio of -415.50x (TTM), a Price-to-Book (P/B) ratio of 1.78x (TTM), at a market cap of $51.11M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -124.60%
- Gross Profit Margin TTM
- 29.27%
- Debt To Equity
- 0.21x
- P/S TTM
- -415.50x
- P/B TTM
- 1.78x
- Market Cap
- $51.11M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Mereo BioPharma Group plc in?
Mereo BioPharma Group plc (MREO) operates in the Pharmaceutical Preparations industry.
What is MREO's market cap?
Mereo BioPharma Group plc (MREO) has a market capitalization of $51.11M as of 2026-06-30.
What exchange does MREO trade on?
Mereo BioPharma Group plc (MREO) trades on the Nasdaq.
Where is Mereo BioPharma Group plc incorporated?
Mereo BioPharma Group plc is incorporated in United Kingdom.